Details:
Under the agreement, BWXT Medical, will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology, enabling Fusion for advancing its pipeline of targeted alpha therapies.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Fusion Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration November 16, 2023
Details:
Under the agreement, Gritstone will have a multi-year option for a non-exclusive license under Genevant’s LNP technology on a pathogen-by-pathogen basis to develop and commercialize self-amplifying RNA (samRNA) vaccines.
Lead Product(s): samRNA Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Gritstone bio
Deal Size: $136.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 15, 2023
Details:
TRIUMF will irradiate thorium-232 targets for BWXT Medical. From this irradiated thorium, BWXT Medical will process and produce high purity n.c.a Ac-225, sometimes referred to as non-carrier-added Ac-225, for commercial sale, strengthening BWXT Medical’s position.
Lead Product(s): n.c.a Ac-225
Therapeutic Area: Oncology Product Name: n.c.a Ac-225
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: TRIUMF
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 13, 2022
Details:
With this agreement with Kinectrics, POINT to access large quantities of highly enriched Yb-176, creating the world’s first, stable North American supply of n.c.a. Lu-177, thereby establishing POINT as a dependable provider of high-quality radiopharmaceuticals.
Lead Product(s): Ytterbium-176
Therapeutic Area: Oncology Product Name: Yb-176
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Point Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 29, 2021
Details:
Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases.
Lead Product(s): Cepharanthine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Pharmadrug Production GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 25, 2021